Binding affinity analysis of quinolone and dione inhibitors with Mtb-DNA gyrase emphasising the crystal water molecular transfer energy to the protein–ligand association

References

• Saxena AK, Singh A. Mycobacterial tuberculosis enzyme targets and their inhibitors. Curr Top Med Chem. 2019;19(5):337–355.
   PubMed Web of Science ®Google Scholar
• Mdluli K, Ma Z. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect Disord Drug Targets. 2007;7:159–168.
   PubMedGoogle Scholar
• Collin F, Karkare S, Maxwell A. Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. Appl Microbiol Biotechnol. 2011;92:479–497.
   PubMed Web of Science ®Google Scholar
• Ma Z, Lienhardt C, McIlleron H, et al. Global tuberculosis drug development pipeline: the need and the reality. Lancet. 2010;375:2100–2109.
   PubMed Web of Science ®Google Scholar
• Drlica K, Mustaev A, Towle T R, et al. Bypassing fluoroquinolone resistance with quinazolinediones: studies of drug–gyrase–DNA complexes having implications for drug design. ACS Chem Biol. 2014;9:2895–2904.
   PubMed Web of Science ®Google Scholar
• Tretter EM, Schoeffler AJ, Weisfield SR, et al. Crystal structure of the DNA gyrase GyrA N-terminal domain from Mycobacterium tuberculosis. Proteins. 2010;78:492–495.
   PubMed Web of Science ®Google Scholar
• Blower TR, Williamson BH, Kerns RJ, et al. Crystal structure and stability of gyrase–fluoroquinolone cleaved complexes from Mycobacterium tuberculosis. PNAS. 2016;113:1706–1713.
   PubMed Web of Science ®Google Scholar
• Nagaraja V, Godbole AA, Henderson SR, et al. DNA topoisomerase I and DNA gyrase as targets for TB therapy. Drug Discov Today. 2017;22:510–518.
   PubMed Web of Science ®Google Scholar
• Ormerod LP. Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. Br Med Bull. 2005;73:17–24.
   PubMed Web of Science ®Google Scholar
• Reece RJ, Maxwell A. DNA gyrase: structure and function. Crit Rev Biochem Mol Biol. 1991;26:335–375.
   PubMed Web of Science ®Google Scholar
• Beard H, Cholleti A, Pearlman D, et al. Applying physics-based scoring to calculate free energies of binding for single amino acid mutations in protein-protein complexes. PloS One. 2013;8:e82849.
   PubMed Web of Science ®Google Scholar
• Steinbrecher T, Zhu C, Wang L, et al. Predicting the effect of amino acid single-point mutations on protein stability large-scale validation of MD-based relative free energy calculations. J Mol Biol. 2017;429:948–963.
   PubMed Web of Science ®Google Scholar
• Aldred KJ, Blower TR, Kerns RJ, et al. Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: enhancing drug activity against wild-type and resistant gyrase. PNAS. 2016;113:E839–E846.
   PubMed Web of Science ®Google Scholar
• Pandey B, Grover S, Tyagi C, et al. Dynamics of fluoroquinolones induced resistance in DNA gyrase of mycobacterium tuberculosis. J Biomol Struct Dyn. 2018;36:362–375.
   PubMed Web of Science ®Google Scholar
• Schrödinger Release. 2021-2: SiteMap. New York (NY): Schrödinger, LLC; 2021.
   Google Scholar
• Halgren TA. Identifying and characterizing binding sites and assessing druggability. J Chem Inf Model. 2009;49(2):377–389.
   PubMed Web of Science ®Google Scholar
• Schrödinger Release. 2021-2: ligprep. New York (NY): Schrödinger, LLC; 2021.
   Google Scholar
• da Cunha EF, Barbosa EF, et al. Molecular modeling of Mycobacterium tuberculosis DNA gyrase and its molecular docking study with gatifloxacin inhibitors. J Biomol Struct Dyn. 2010;27:619–625.
   PubMed Web of Science ®Google Scholar
• Schrödinger Release. 2021-2: Desmond molecular dynamics system. New York, NY: D. E. Shaw Research; 2021.
   Google Scholar
• Roos K, Wu C, Damm W, et al. OPLS3e: extending force field coverage for drug-like small molecules. J Chem Theory Comput. 2019;15(3):1863–1874.
   PubMed Web of Science ®Google Scholar
• Andersen HC. Rattle: A ‘velocity’ version of the shake algorithm for molecular dynamics calculations. J Comput Phys. 1983;52(1):24–34.
   Web of Science ®Google Scholar
• Darden T, York D, Pedersen L. Particle mesh Ewald: An N ⋅ log (N) method for Ewald sums in large systems. J Chem Phys. 1993;98(12):10089–10092.
   Web of Science ®Google Scholar
• Schrödinger Release. 2021-2: prime. New York, NY: Schrödinger, LLC; 2021.
   Google Scholar
• Alvarez N, Zapata E, Mejia G, et al. The structural modeling of the interaction between levofloxacin and the Mycobacterium tuberculosis gyrase catalytic site sheds light on the mechanisms of fluoroquinolones resistant tuberculosis in Colombian clinical isolates. BioMed Res Int. 2014;vol. 2014, 9 pages.
   Web of Science ®Google Scholar
• Piton J, Petrella S, Delarue M, et al. Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrase. PLoS One. 2010;5:e12245.
   PubMed Web of Science ®Google Scholar
• Rigouts L, Coeck N, Gumusboga M, et al. Specific gyrA gene mutations predict poor treatment outcome in MDR-TB. J Antimicrob Chemother. 2015;71:314–323.
   PubMed Web of Science ®Google Scholar
• Minovski N, Perdih A, Novic M, et al. Cluster-based molecular docking study for in silico identification of novel 6-fluoroquinolones as potential inhibitors against Mycobacterium tuberculosis. J Comput Chem. 2013;34:790–801.
   PubMed Web of Science ®Google Scholar
• Anand R, Somasundaram S, Doble M, et al. Docking studies on novel analogues of 8 methoxy fluoroquinolones against GyrA mutants of Mycobacterium tuberculosis. BMC Struct Biol. 2011;11:47.
   PubMed Web of Science ®Google Scholar
• Pandey B, Grover S, Tyagi C, et al. Double mutants in DNA gyrase lead to ofloxacin resistance in mycobacterium tuberculosis. J Cell Biochem. 2017;118(9):2950–2957.
   PubMed Web of Science ®Google Scholar
• Maruri F, Sterling TR, Kaiga AW, et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother. 2012;67(4):819–831.
   PubMed Web of Science ®Google Scholar
• Sirgel FA, Warren RM, Streicher EM, et al. Gyra mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother. 2012;67(5):1088–1093.
   PubMed Web of Science ®Google Scholar
• Evans J, Segal H. Novel multiplex allele-specific PCR assays for the detection of resistance to second-line drugs in Mycobacterium tuberculosis. J Antimicrob Chemother. 2010;65(5):897–900.
   PubMed Web of Science ®Google Scholar